Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Keywords:
Materias Investigacion::Ciencias de la Salud::Oncología
Anti-EGFR
Antiangiogenic drugs
Dermatological toxicity
Immune checkpoint inhibitors
MTOR inhibitors
Targeted therapies
Publisher:
Springer Science and Business Media LLC
Note:
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat ivecommons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Citation:
Grávalos, C. (C.); Sanmartín, O. (O.); Gurpide, A. (Alfonso); et al. "Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology". Clinical and Translational Oncology. 21 (5), 2019, 556 - 571
Statistics and impact
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.